lumiracoxib (Prexige)

From Aaushi
Jump to navigation Jump to search

Introduction

approved in the UK, but not yet in the US.)[1][2][3]

Indications

Dosage

Adverse effects

Mechanism of action

More general terms

References

  1. 1.0 1.1 Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004 Aug 21;364(9435):665-74. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15325831
  2. 2.0 2.1 Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004 Aug 21;364(9435):675-84. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15325832
  3. 3.0 3.1 3.2 Journal Watch 24(19):149, 2004
  4. Hawkey CJ et al. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin Gastroenterol Hepatol 2008 May; 6:536. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18242145

Database